Ligand id: 9723

Name: (+)-SJ733

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 86.09
Molecular weight 468.12
XLogP 3.8
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
(+)-SJ733 was in clinical development with recent completion of Phase 1 trials (NCT02661373 and NCT02867059).
Mechanism Of Action and Pharmacodynamic Effects
The exact mechanism of action of (+)-SJ733 is not fully understood but Plasmodium non-SERCA-type Ca2+-transporting P-ATPase (PfATP4) may be the potential target because mutatations in PfATP4 confer resistance to this compound [1]. (+)-SJ733 produces a rapid perturbation of parasitic intracellular Na+ levels, in concurrence with the proposed role of PfATP4 in the regulation of Na+ homeostasis, followed by physical changes in the infected erythrocytes. It has been proposed that host-mediated clearance of infected cells may be responsible for the rapid action of PfATP4 inhibitors [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02661373 First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor Phase 1 Interventional St. Jude Children's Research Hospital
NCT02867059 SJ733 Induced Blood Stage Malaria Challenge Study Phase 1 Interventional Medicines for Malaria Venture